ChiCTR2300074272 版本V1.0 版本创建时间2023/08/02 16:48:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300074272 

最近更新日期:

Date of Last Refreshed on:

2023-08-02 16:48:12 

注册时间:

Date of Registration:

2023-08-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

膈肌、肋间肌超声在ICU机械通气患者中的应用

Public title:

The application of diaphragm and intercostal muscle ultrasound in patients with mechanical ventilation in ICU

注册题目简写:

English Acronym:

研究课题的正式科学名称:

膈肌、肋间肌超声在ICU机械通气患者中的应用

Scientific title:

The application of diaphragm and intercostal muscle ultrasound in patients with mechanical ventilation in ICU

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

彭丽 

研究负责人:

彭丽 

Applicant:

Li Peng 

Study leader:

Li Peng 

申请注册联系人电话:

Applicant telephone:

+86 157 3181 1868

研究负责人电话:

Study leader's
telephone:

+86 157 3181 1868

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

455902511@qq.com

研究负责人电子邮件:

Study leader's E-mail:

455902511@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河北省衡水市人民东路180号

研究负责人通讯地址:

河北省衡水市人民东路180号

Applicant address:

No. 180, Renmin East Road, Hengshui City, Hebei Province

Study leader's address:

No. 180, Renmin East Road, Hengshui City, Hebei Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

衡水市人民医院 (哈励逊国际和平医院)

Applicant's institution:

Hengshui People's Hospital (Harrison International Peace Hospital)

研究负责人所在单位:

衡水市人民医院 (哈励逊国际和平医院)

Affiliation of the Leader:

Hengshui People's Hospital (Harrison International Peace Hospital)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-1-043

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

衡水市人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Hengshui People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-06-30 00:00:00

伦理委员会联系人:

姜瑞博

Contact Name of the ethic committee:

Ruibo Jiang

伦理委员会联系地址:

河北省衡水市人民东路180号

Contact Address of the ethic committee:

No. 180, Renmin East Road, Hengshui City, Hebei Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 318 218 3377

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

衡水市人民医院(哈励逊国际和平医院)

Primary sponsor:

Hengshui People's Hospital(Harrison International Peace Hospital)

研究实施负责(组长)单位地址:

河北省衡水市人民东路180号

Primary sponsor's address:

No. 180, Renmin East Road, Hengshui City, Hebei Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北省

市(区县):

Country:

China

Province:

Hebei Province

City:

单位(医院):

衡水市人民医院

具体地址:

河北省衡水市人民东路180号

Institution
hospital:

Hengshui People's Hospital

Address:

No. 180, Renmin East Road, Hengshui City, Hebei Province

经费或物资来源:

2023年度河北省医学科学研究课题

Source(s) of funding:

2023 Medical Science Research Project of Hebei Province

研究疾病:

有创机械通气患者  

Target disease:

Mechanical ventilation patients

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

1、探讨胸骨旁肋间肌增厚分数与膈肌增厚分数比值(TFic/TFdi)预测撤机结局的准确性,并与膈肌浅快呼吸指数比较明确其预测撤机结局的能力。 2、明确ICU机械通气患者基线呼吸肌肌肉厚度、肌肉厚度变化及呼吸肌功能与撤机结局的关系。  

Objectives of Study:

1. Our primary objective is to evaluate the performance of the ratio of parasternal intercostal muscle thickening fraction to diaphragmatic thickening fraction (TFic/TFdi) to predicti the weaning outcome ;and to compare the ability of TFic/TFdi and diaphragmatic rapid shallow breathing index to predict weaning outcome. 2. Our second objective is to determine whether baseline respiratory muscle thickness ,loss of muscle thickness and respiratory muscle function are associated with weaning outcome among mechanical ventilation patients in ICU

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①年龄≥18岁;②经口气管插管且预计ICU机械通气时间≥48h的患者;

Inclusion criteria

(a)Age≥18 years, (b)Patients intubated and mechanically ventilated for more than 48 h

排除标准:

①年龄<18岁;②神经肌肉疾病、脊髓损伤;③妊娠;④首次SBT前48h内应用肌松剂;⑤气管切开、气胸、肋骨骨折、纵膈气肿、横膈解剖畸形或膈肌超声发现一侧膈肌功能异常者;⑥超声图像不清晰者

Exclusion criteria:

(a) age <18 years; (b) neuromuscular disease,Spinal cord injury;(c)pregnancy; (d) use of muscle-paralyzing agents within 48 h before first SBT; (e) presence of thoracostomy, pneumothorax, or flail chest or rib fractures ,pneumomediastinum and history or new detection of paralysis or paradoxical movement of a single hemidiaphragm on diaphragmatic ultrasonography; (f )unclear of the ultrasound image

研究实施时间:

Study execute time:

From 2023-08-10 00:00:00 To 2026-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-08-10 00:00:00 To 2024-12-31 00:00:00

干预措施:

Interventions:

组别:

连续入组

样本量:

83

Group:

case series

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北省 

市(区县):

 

Country:

China

Province:

Hebei Province

City:

单位(医院):

衡水市人民医院重症医学科 

单位级别:

三甲 

Institution
hospital:

Intensive care unit,Hengshui People's Hospital

Level of the institution:

tertiary A

测量指标:

Outcomes:

指标中文名:

胸骨旁肋间肌增厚分数与膈肌增厚分数比值

指标类型:

主要指标

Outcome:

The ratio of parasternal intercostal muscle thickening fraction to diaphragmatic thickening fraction (TFic/TFdi)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膈肌浅快呼吸指数

指标类型:

主要指标

Outcome:

diaphragmatic rapid shallow breathing index(D-RSBI)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膈肌位移

指标类型:

主要指标

Outcome:

diaphragmatic excursion

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膈肌增厚分数

指标类型:

主要指标

Outcome:

diaphragm thicking fraction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

No

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-08-02 16:48:12